BSSG is a glucosylated sterol, a molecule built from a steroid backbone linked to a glucose moiety. It first attracted scientific attention decades ago in the Western Pacific, where an unusually high incidence of a disorder combining ALS-like motor neuron loss, parkinsonism and dementia was documented among the indigenous Chamorro population of Guam, and later in the Kii peninsula of Japan and Western New Guinea. The common thread turned out to be dietary: communities in these regions traditionally consumed flour made from cycad seeds, which contain considerable concentrations of BSSG. When Western dietary habits spread and cycad consumption declined after World War II, the incidence of ALS-PDC fell sharply. Previous work has shown that BSSG is neurotoxic in cell culture and in animals, driving glutamate-mediated excitotoxicity, promoting the accumulation of hyperphosphorylated tau in neurons and exacerbating apoptosis in astrocytes. Mice fed BSSG develop a pre-symptomatic ALS-PDC-like phenotype, but the earliest steps of the molecule’s path through the body have remained poorly charted.

To trace those steps, the team administered BSSG to zebrafish larvae and adults, either directly in the water at 10 micromolar or through customized BSSG-enriched food pellets, and to mice receiving 1 milligram per day, five days a week, for fifteen weeks. Mass spectrometry of lipid extracts confirmed that the compound accumulated in the trunk region of treated larvae, which contains the intestine. What happened next was unexpected: rather than an immediate neurological signature, the first visible target was the gut. Nearly all BSSG-exposed larvae developed dark aggregates in the intestine, prompting the researchers to look more closely at intestinal physiology.

The evidence of inflammation was striking and multi-layered. In vivo staining with neutral red revealed a reduction in lysosome-rich enterocytes, a well-established marker of intestinal injury in zebrafish models. The number of mucus-secreting goblet cells, which shield the intestinal wall from digestive enzymes and pathogens, dropped significantly, and the expression of agr2, a gene essential for mucus production, fell in parallel. At the same time, fluorescent neutrophils infiltrated the mid-intestine in dramatically higher numbers in a transgenic reporter line, and a separate NF-κB reporter line lit up along the gut wall, indicating activation of a central inflammatory signaling pathway. Acridine Orange staining revealed increased cell death, while a Stat3 reporter suggested depletion of the stem-like cells at the bases of intestinal folds, the zebrafish counterparts of mammalian crypt base columnar cells that normally replenish the epithelial lining.

Crucially, the effect was specific to the glucosylated form. β-sitosterol, which shares BSSG’s steroid structure but lacks the glucose moiety, produced none of these intestinal changes, pointing to the sugar group as the molecular feature responsible for the damage. That distinction matters beyond the aquarium: elevated levels of glucosyl-β-d-cholesterol, an endogenous human glucosylated sterol, are found in patients carrying GBA1 mutations, a major genetic risk factor for Parkinson’s disease, while glucosyl-α-d-cholesterol is produced by Helicobacter pylori during gastric infections, itself linked to increased lifetime risk of Parkinson’s. The mechanisms connecting these sterols to nervous system damage have remained obscure, and the new results suggest the intestine may be where the story begins.

Gut inflammation was only the opening act. Treated zebrafish larvae showed a marked reduction in peristaltic contractions and significantly delayed gastrointestinal transit, hallmarks of disturbed intestinal motility that in humans often precede the motor symptoms of Parkinson’s disease and ALS by years. Notably, counts of enteric neurons and their progenitors were unchanged, suggesting that BSSG impairs the function of the enteric nervous system rather than its structure. The team then performed what they describe as the first ex vivo analysis of neuromuscular contractility in isolated adult zebrafish intestines, mounting whole guts in oxygenated organ baths and measuring tension with isometric force transducers. Treated intestines contracted more forcefully in response to potassium chloride depolarization, to the cholinergic agonist carbachol, and to electrical field stimulation of enteric neurons, while relaxation in response to a β-adrenergic agonist was unaffected. The pattern points to hypercontractility of both the muscular and neuronal components of the gut wall, a profile reminiscent of inflammatory bowel disease.

Molecular profiling deepened the picture. RNA sequencing of chronically treated larvae identified 261 differentially expressed genes, with upregulated genes concentrated in acute inflammatory response, defense against bacteria and response to reactive oxygen species. Markers such as mmp9, pept1, saa and s100a10a, which mirrors human calprotectin, an established inflammatory bowel disease marker also elevated in Parkinson’s and Alzheimer’s patients, were all increased. The entire suite of hemoglobin genes was downregulated, a change recently associated with the pathophysiology of several neurodegenerative diseases. In the brains of adult treated zebrafish, autophagy-related genes including atg5, lc3b and p62 were reduced, hinting at a possible impairment of the cellular waste-clearance process whose failure promotes neurotoxic protein aggregates.

The mouse experiments confirmed that the phenomenon crosses species. After fifteen weeks on the BSSG diet, mice showed increased macrophages in the lamina propria of the small intestine, fewer goblet cells, and significantly shortened microvilli under electron microscopy, suggesting impaired absorptive capacity. Treated mice weighed less than controls despite eating the same amount. RNA sequencing of mouse gut tissue revealed 1,835 differentially expressed genes dominated by immune response categories, with upregulation of Toll-like receptors 2, 4 and 6, the inflammasome component Nlrp3, the pro-inflammatory cytokines IL-1β and IFN-γ, and, notably, Lrrk2, one of the most significant genetic risk factors for Parkinson’s disease, whose protein promotes NF-κB signaling in the gut. The antimicrobial peptide Reg3-γ was downregulated, mirroring the goblet cell loss. Preliminary fecal microbiota sequencing also suggested early dysbiosis, with an expansion of potentially pathogenic families such as Bacteroidaceae and Helicobacteraceae and a reduction of anti-inflammatory Lachnospiraceae.

Perhaps the most intriguing mechanistic clue came from BSSG’s structural kinship with steroid hormones. In a radioligand binding assay, BSSG displaced about 12.5 percent of radiolabeled dexamethasone from the glucocorticoid receptor, while leaving estrogen, mineralocorticoid and progesterone receptors untouched. To test this in living animals, the researchers exploited zebrafish mutants unable to synthesize active glucocorticoids, crossed with a transgenic line whose intestines glow green when the glucocorticoid receptor is activated. BSSG treatment significantly increased intestinal fluorescence in these receptor-reporter animals, indicating that the molecule can engage the receptor in vivo. Even more tellingly, zebrafish engineered to lack the glucocorticoid receptor entirely were largely protected: their goblet cell numbers, inflammatory gene expression, gut contractility and microbiota composition barely changed with BSSG exposure. Because the glucocorticoid receptor normally suppresses inflammation in the intestine, the results suggest BSSG may sabotage this built-in anti-inflammatory brake.

The authors propose a model in which dietary BSSG first inflames the gut, weakening the epithelial barrier, disturbing motility and shifting the microbiome, and then, through disruption of the gut–brain axis, predisposes the nervous system to degeneration, ultimately culminating in ALS-PDC. While the glucocorticoid receptor interaction still requires in vitro validation, altered glucocorticoid signaling has already been implicated in ALS, Parkinson’s and Alzheimer’s disease. If the model holds, restoring intestinal homeostasis could become an early intervention strategy, targeting the disease at its apparent point of origin rather than its neurological endpoint.

Neurons possess a limited intrinsic ability to store and detoxify lipids, rendering them heavily reliant on astrocytes to maintain lipid homeostasis. This dependency places astrocytes at the frontline of protecting neurons from lipid-induced toxicity. Importantly, Kim and Halliday’s review underscores that disruptions in astrocytic lipid metabolism are among the earliest detectable events preceding neuronal degeneration in numerous neurodegenerative disorders.

Conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, and Huntington’s disease have all been linked to significant perturbations in astrocytic lipid handling. When the lipid regulatory functions of astrocytes become compromised, this leads to maladaptive reactive states. These states exacerbate oxidative stress, impair organelle functions—particularly lysosomes and mitochondria—and disturb the critical lipid exchange between neurons and glia, cumulatively fostering a neurotoxic milieu conducive to degeneration.

The mechanistic insights presented by Kim and Halliday reveal that astrocytic lipid dysregulation is not merely a passive consequence of neurodegeneration but might act as an instructive, early driver of neuronal vulnerability. Contrary to being categorically protective or pathological, astrocytic lipid metabolism plays nuanced physiological roles that, when disrupted, can tip the balance toward disease.

This paradigm shift implicates astrocytes as promising therapeutic targets. By restoring or modulating lipid homeostasis within these glial cells, it may be possible to halt or delay the progression of neurodegenerative diseases. Beyond treatment, understanding astrocyte lipid dynamics opens new avenues for early biomarker detection, offering the potential for pre-symptomatic diagnosis.

The review critically differentiates between correlative findings and causal pathways, advocating for more targeted studies to unravel the precise molecular mechanisms by which astrocytic lipid dysregulation triggers neuronal compromise. This insight challenges previously neuron-centric models of neurodegeneration and suggests that glia-centered interventions could revolutionize clinical approaches.

Ultimately, the emerging evidence positions astrocytes as central players in neurological health, emphasizing the need to reconsider their role in the etiology of neurodegenerative diseases. By focusing on the metabolic underpinnings governed by astrocytes, researchers may unlock novel strategies for diagnosis, intervention, and possibly prevention of some of the most devastating brain disorders.

Subject of Research: Astrocytic lipid metabolism and its role in neurodegeneration

Article Title: Astrocytic lipid dysregulation as an early driver of neurodegeneration

Article References:
Kim, W.S., Halliday, G.M. Astrocytic lipid dysregulation as an early driver of neurodegeneration. Nat Rev Neurol (2026). https://doi.org/10.1038/s41582-026-01238-3

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01238-3

Keywords: Astrocytes, lipid metabolism, neurodegeneration, oxidative stress, cholesterol synthesis, reactive astrocytes, neurodegenerative diseases